Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q2 2020 · 10-Q
Revenue$612.31K$612.31K+1,331.5% vs Q2 2019 Net Income-$373.35K-$373.35KN/M vs Q2 2019 EPS Diluted-$0.02-$0.02N/M vs Q2 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$886,963N/M Free Cash Flowderived-$889,983N/M Margins · derivedGross margin31.7%+44.4 pt vs Q2 2019
Operating margin-67.9%+652.5 pt vs Q2 2019
Net margin-61.0%+449.6 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 13, 2020 · 44 d after period end